Do analysts rate ICCC or BIOA?

BioAge Labs has a consensus target price of $36.57, indicating a potential upside of 453.27%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher valuation & earnings, ICCC or BIOA?

ImmuCell has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.20 -$1.04M $0.08 121.88 BioAge Labs $8.99M 33.75 -$80.61M -$2.38 N/A

Is ICCC or BIOA more profitable?

ImmuCell has a net margin of 2.57% compared to BioAge Labs' net margin of -912.26%. ImmuCell's return on equity of 2.69% beat BioAge Labs' return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell 2.57% 2.69% 1.76% BioAge Labs -912.26% -28.99% -27.09%

Do analysts rate VNDA or ICCC?

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 182.58%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend ICCC or IKT?

Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 170.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Do analysts recommend EYPT or ICCC?

Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 690.77%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer AMRN or ICCC?

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 5.26%. Given Amarin's higher possible upside, analysts plainly believe Amarin is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, AMRN or ICCC?

ImmuCell has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $186.23M 1.40 -$38.80M -$0.99 N/A ImmuCell $27.64M 3.20 -$1.04M $0.08 121.88

Is AMRN or ICCC more profitable?

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% ImmuCell 2.57% 2.69% 1.76%

ImmuCell (ICCC) Competitors

$9.75 +0.15 (+1.56%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.68 -0.06 (-0.67%)

As of 10/2/2026 04:10 PM Eastern

Compare

ICCC vs. BIOA, VNDA, IKT, EYPT, and AMRN

Should you buy ImmuCell stock or one of its competitors? ImmuCell's main competitors and comparable companies include BioAge Labs (BIOA), Vanda Pharmaceuticals (VNDA), Inhibikase Therapeutics (IKT), Eyepoint Pharmaceuticals (EYPT), and Amarin (AMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ImmuCell compare to BioAge Labs?

ImmuCell (NASDAQ:ICCC) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

13.5% of ImmuCell shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 17.6% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ImmuCell has a net margin of 2.57% compared to BioAge Labs' net margin of -912.26%. ImmuCell's return on equity of 2.69% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, BioAge Labs had 4 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for BioAge Labs and 0 mentions for ImmuCell. BioAge Labs' average media sentiment score of 0.62 beat ImmuCell's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Neutral
BioAge Labs	Positive

ImmuCell has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

ImmuCell has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88
BioAge Labs	$8.99M	33.75	-$80.61M	-$2.38	N/A

BioAge Labs has a consensus target price of $36.57, indicating a potential upside of 453.27%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

ImmuCell and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vanda Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 11 more articles in the media than ImmuCell. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 0 mentions for ImmuCell. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat ImmuCell's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Neutral
ImmuCell	Neutral

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 182.58%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.30	-$220.47M	-$4.63	N/A
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88

ImmuCell has a net margin of 2.57% compared to Vanda Pharmaceuticals' net margin of -127.41%. ImmuCell's return on equity of 2.69% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
ImmuCell	2.57%	2.69%	1.76%

Summary

Vanda Pharmaceuticals beats ImmuCell on 9 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Inhibikase Therapeutics?

ImmuCell (NASDAQ:ICCC) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

ImmuCell has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 170.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 0 mentions for ImmuCell. Inhibikase Therapeutics' average media sentiment score of 0.51 beat ImmuCell's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Neutral
Inhibikase Therapeutics	Positive

ImmuCell has a net margin of 2.57% compared to Inhibikase Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmuCell has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Summary

Inhibikase Therapeutics beats ImmuCell on 9 of the 17 factors compared between the two stocks.

How does ImmuCell compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than ImmuCell. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 0 mentions for ImmuCell. Eyepoint Pharmaceuticals' average media sentiment score of 0.34 beat ImmuCell's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
ImmuCell	Neutral

ImmuCell has a net margin of 2.57% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. ImmuCell's return on equity of 2.69% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
ImmuCell	2.57%	2.69%	1.76%

ImmuCell has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.93	-$231.96M	-$3.74	N/A
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88

Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 690.77%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Eyepoint Pharmaceuticals beats ImmuCell on 9 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Amarin?

Amarin (NASDAQ:AMRN) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Amarin's average media sentiment score of 1.88 beat ImmuCell's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Very Positive
ImmuCell	Neutral

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
ImmuCell	2.57%	2.69%	1.76%

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 5.26%. Given Amarin's higher possible upside, analysts plainly believe Amarin is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.3% of Amarin shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ImmuCell has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$186.23M	1.40	-$38.80M	-$0.99	N/A
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88

Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

ImmuCell beats Amarin on 9 of the 14 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$88.55M	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.32%
P/E Ratio	121.89	799.70	275.66	26.04
Price / Sales	3.20	752.92	609.46	91.89
Price / Cash	50.57	86.66	78.87	52.62
Price / Book	3.26	10.46	10.93	6.31
Net Income	-$1.04M	$2.84B	$3.51B	$362.16M
7 Day Performance	-1.81%	-1.57%	-2.00%	-1.66%
1 Month Performance	-2.50%	-5.67%	-6.15%	-4.50%
1 Year Performance	54.52%	-4.73%	7.44%	2.06%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	0.6089 of 5 stars	$9.75 +1.6%	N/A	+48.9%	$88.55M	$27.64M	121.89	73
BIOA BioAge Labs	3.0594 of 5 stars	$7.09 -0.7%	$36.57 +415.8%	+12.0%	$325.43M	$8.99M	N/A	62
VNDA Vanda Pharmaceuticals	2.7773 of 5 stars	$4.91 -2.4%	$13.08 +166.5%	-10.3%	$296.87M	$215.72M	N/A	533	News Coverage
IKT Inhibikase Therapeutics	2.4388 of 5 stars	$2.06 +2.0%	$5.40 +162.1%	+22.0%	$287.44M	N/A	N/A	35	News Coverage
EYPT Eyepoint Pharmaceuticals	2.8604 of 5 stars	$3.27 -4.4%	$25.70 +685.9%	-75.9%	$281.91M	$2.79M	N/A	214	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. BIOA, VNDA, IKT, EYPT, and AMRN

How does ImmuCell compare to BioAge Labs?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Summary

How does ImmuCell compare to Inhibikase Therapeutics?

Summary

How does ImmuCell compare to Eyepoint Pharmaceuticals?

Summary

How does ImmuCell compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. BIOA, VNDA, IKT, EYPT, and AMRN

How does ImmuCell compare to BioAge Labs?

Do insiders and institutionals have more ownership in ICCC or BIOA?

Is ICCC or BIOA more profitable?

Does the media favor ICCC or BIOA?

Which has more risk and volatility, ICCC or BIOA?

Which has higher valuation & earnings, ICCC or BIOA?

Do analysts rate ICCC or BIOA?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Do institutionals and insiders hold more shares of VNDA or ICCC?

Which has more risk & volatility, VNDA or ICCC?

Does the media refer more to VNDA or ICCC?

Do analysts rate VNDA or ICCC?

Which has stronger valuation & earnings, VNDA or ICCC?

Is VNDA or ICCC more profitable?

Summary

How does ImmuCell compare to Inhibikase Therapeutics?

Which has better earnings and valuation, ICCC or IKT?

Do analysts recommend ICCC or IKT?

Does the media refer more to ICCC or IKT?

Is ICCC or IKT more profitable?

Do institutionals & insiders hold more shares of ICCC or IKT?

Which has more risk and volatility, ICCC or IKT?

Summary

How does ImmuCell compare to Eyepoint Pharmaceuticals?

Which has more volatility and risk, EYPT or ICCC?

Does the media prefer EYPT or ICCC?

Is EYPT or ICCC more profitable?

Which has better earnings and valuation, EYPT or ICCC?

Do analysts recommend EYPT or ICCC?

Do insiders & institutionals hold more shares of EYPT or ICCC?

Summary

How does ImmuCell compare to Amarin?

Does the media refer more to AMRN or ICCC?

Is AMRN or ICCC more profitable?

Do analysts prefer AMRN or ICCC?

Do institutionals and insiders have more ownership in AMRN or ICCC?

Which has higher valuation & earnings, AMRN or ICCC?

Which has more risk & volatility, AMRN or ICCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools